http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103585130-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea9ad1bdd7bb25b303e4330b4d1a1f04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 2013-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a689125dd6919b4df4b9ff78f6ae1a0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb4d92364063fe14b0dc5578b38b9215 |
| publicationDate | 2015-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103585130-B |
| titleOfInvention | Lansoprazole enteric capsule and preparation method thereof |
| abstract | The invention relates to the preparation field, in particular to a lansoprazole enteric capsule and a preparation method thereof, and aims to provide the ansoprazole enteric capsule and the preparation method thereof, reduce the complicated degree of an existing process and achieve purposes of stable release of the capsule at the small intestine part, stable and reliable quality and high bioavailability. The technical key point of the ansoprazole enteric capsule lies in material selection of a micro-capsule and control of the particle size of a capsule core material. The capsule core and a capsule material comprise components in parts by weight as follows: the capsule core comprises 45-50 parts of lansoprazole micro powder; and the capsule material comprises 4-6 parts of chitosan, 2-4 parts of Arabic gum and 3-5 parts of phthalic acid hydroxypropyl methyl cellulose. The capsule core material is a micronized lansoprazole active ingredient, optimally, the particle sizes of 95% of the micronized lansoprazole active ingredients are smaller than 6 mu m, the prepared capsule is high in encapsulation efficiency, drug loading efficiency and main drug dissolution rate and good in fluidity when the particle size of the lansoprazole active ingredient is micronized to be smaller than 6 mu m, and the releasing rate and the bioavailability of the drug can be improved. |
| priorityDate | 2013-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.